GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (OTCPK:NVSEF) » Definitions » EV-to-EBIT

Novartis AG (Novartis AG) EV-to-EBIT

: 19.63 (As of Today)
View and export this data going back to 1996. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Novartis AG's Enterprise Value is $202,405 Mil. Novartis AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $10,312 Mil. Therefore, Novartis AG's EV-to-EBIT for today is 19.63.

The historical rank and industry rank for Novartis AG's EV-to-EBIT or its related term are showing as below:

NVSEF' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.22   Med: 19.19   Max: 24.58
Current: 19.63

During the past 13 years, the highest EV-to-EBIT of Novartis AG was 24.58. The lowest was 7.22. And the median was 19.19.

NVSEF's EV-to-EBIT is ranked worse than
58.68% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.04 vs NVSEF: 19.63

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Novartis AG's Enterprise Value for the quarter that ended in Dec. 2023 was $216,872 Mil. Novartis AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $10,312 Mil. Novartis AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.75%.


Novartis AG EV-to-EBIT Historical Data

The historical data trend for Novartis AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.35 21.22 7.41 23.77 21.35

Novartis AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.77 21.93 21.75 22.38 21.35

Competitive Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Novartis AG's EV-to-EBIT falls into.



Novartis AG EV-to-EBIT Calculation

Novartis AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=202405.265/10312
=19.63

Novartis AG's current Enterprise Value is $202,405 Mil.
Novartis AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,312 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novartis AG  (OTCPK:NVSEF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Novartis AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=10312/216872
=4.75 %

Novartis AG's Enterprise Value for the quarter that ended in Dec. 2023 was $216,872 Mil.
Novartis AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,312 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novartis AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Novartis AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (Novartis AG) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.